Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity

References

1. 1.↵
   2. Barkhof F

   . MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999;5:283–86 doi:10.1177/135245859900500415 pmid:10467389

   Abstract/FREE Full Text
2. 2.↵
   2. Lucchinetti C,
   3. Brück W,
   4. Parisi J, et al

   . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–17 pmid:10852536

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Kutzelnigg A,
   3. Lucchinetti CF,
   4. Stadelmann C, et al

   . Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(pt 11):2705–12 doi:10.1093/brain/awh641 pmid:16230320

   Abstract/FREE Full Text
4. 4.↵
   2. Rauscher A,
   3. Sedlacik J,
   4. Barth M, et al

   . Magnetic susceptibility-weighted MR phase imaging of the human brain. AJNR Am J Neuroradiol 2005;26:736–42 pmid:15814914

   Abstract/FREE Full Text
5. 5.↵
   2. Deistung A,
   3. Rauscher A,
   4. Sedlacik J, et al

   . Susceptibility weighted imaging at ultra high magnetic field strengths: theoretical considerations and experimental results. Magn Reson Med 2008;60:1155–68 doi:10.1002/mrm.21754 pmid:18956467

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Langkammer C,
   3. Krebs N,
   4. Goessler W, et al

   . Susceptibility induced gray-white matter MRI contrast in the human brain. Neuroimage 2012;59:1413–19 doi:10.1016/j.neuroimage.2011.08.045 pmid:21893208

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Bagnato F,
   3. Hametner S,
   4. Yao B, et al

   . Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134(pt 12):3602–15 doi:10.1093/brain/awr278 pmid:22171355

   Abstract/FREE Full Text
8. 8.↵
   2. Yao B,
   3. Bagnato F,
   4. Matsuura E, et al

   . Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012;262:206–15 doi:10.1148/radiol.11110601 pmid:22084205

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Absinta M,
   3. Sati P,
   4. Gaitán MI, et al

   . Seven-Tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013;74:669–78 doi:10.1002/ana.23959 pmid:23813441

   CrossRefPubMed
10. 10.↵
    2. Hammond KE,
    3. Metcalf M,
    4. Carvajal L, et al

    . Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13 doi:10.1002/ana.21582 pmid:19107998

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Deistung A,
    3. Schäfer A,
    4. Schweser F, et al

    . Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength. Neuroimage 2013;65:299–314 doi:10.1016/j.neuroimage.2012.09.055 pmid:23036448

    CrossRefPubMed
12. 12.↵
    2. Stuber C,
    3. Morawski M,
    4. Schäfer A, et al

    . Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. Neuroimage 2014;93(pt 1):95–106 doi:10.1016/j.neuroimage.2014.02.026 pmid:24607447

    CrossRefPubMed
13. 13.↵
    2. Eskreis-Winkler S,
    3. Deh K,
    4. Gupta A, et al

    . Multiple sclerosis lesion geometry in quantitative susceptibility mapping (QSM) and phase imaging. J Magn Reson Imaging 2015;42:224–29 doi:10.1002/jmri.24745 pmid:25174493

    CrossRefPubMed
14. 14.↵
    2. Liu C,
    3. Li W,
    4. Tong KA, et al

    . Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging 2015;42:23–41 doi:10.1002/jmri.24768 pmid:25270052

    CrossRefPubMed
15. 15.↵
    2. Wang Y,
    3. Liu T

    . Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 2015;73:82–101 doi:10.1002/mrm.25358 pmid:25044035

    CrossRefPubMed
16. 16.↵
    2. Wharton S,
    3. Bowtell R

    . Whole-brain susceptibility mapping at high field: a comparison of multiple- and single-orientation methods. Neuroimage 2010;53:515–25 doi:10.1016/j.neuroimage.2010.06.070 pmid:20615474

    CrossRefPubMed
17. 17.↵
    2. Li X,
    3. Harrison DM,
    4. Liu H, et al

    . Magnetic susceptibility contrast variations in multiple sclerosis lesions. J Magn Reson Imaging 2016;43:463–73 doi:10.1002/jmri.24976 pmid:26073973

    CrossRefPubMed
18. 18.↵
    2. Li X,
    3. Vikram DS,
    4. Lim IA, et al

    . Mapping magnetic susceptibility anisotropies of white matter in vivo in the human brain at 7 T. Neuroimage 2012;62:314–30 doi:10.1016/j.neuroimage.2012.04.042 pmid:22561358

    CrossRefPubMed
19. 19.↵
    2. Miller AJ,
    3. Joseph PM

    . The use of power images to perform quantitative analysis on low SNR MR images. Magn Reson Imaging 1993;11:1051–56 doi:10.1016/0730-725X(93)90225-3 pmid:8231670

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Li W,
    3. Wu B,
    4. Liu C

    . Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 2011;55:1645–56 doi:10.1016/j.neuroimage.2010.11.088 pmid:21224002

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Li W,
    3. Avram AV,
    4. Wu B, et al

    . Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. NMR Biomed 2014;27:219–27 doi:10.1002/nbm.3056 pmid:24357120

    CrossRefPubMed
22. 22.↵
    2. Fischer JS,
    3. Rudick RA,
    4. Cutter GR, et al

    . The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment—National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244–50 doi:10.1177/135245859900500409 pmid:10467383

    Abstract/FREE Full Text
23. 23.↵
    2. Rudick R,
    3. Antel J,
    4. Confavreux C, et al

    . Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379–82 doi:10.1002/ana.410420318 pmid:9307263

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Flachenecker P,
    3. Kümpfel T,
    4. Kallmann B, et al

    . Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8:523–26 doi:10.1191/1352458502ms839oa pmid:12474995

    Abstract/FREE Full Text
25. 25.↵
    2. Achiron A,
    3. Givon U,
    4. Magalashvili D, et al

    . Effect of Alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult Scler 2015;21:767–75 doi:10.1177/1352458514554053 pmid:25344375

    Abstract/FREE Full Text
26. 26.↵
    2. Laird NM,
    3. Ware JH

    . Random-effects models for longitudinal data. Biometrics 1982;38:963–74 doi:10.2307/2529876 pmid:7168798

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Wiggermann V,
    3. Hernandez Torres E,
    4. Vavasour IM, et al

    . Magnetic resonance frequency shifts during acute MS lesion formation. Neurology 2013;81:211–18 doi:10.1212/WNL.0b013e31829bfd63 pmid:23761621

    Abstract/FREE Full Text
28. 28.↵
    2. Yablonskiy DA,
    3. Luo J,
    4. Sukstanskii AL, et al

    . Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis. Proc Natl Acad Sci U S A 2012;109:14212–17 doi:10.1073/pnas.1206037109 pmid:22891307

    Abstract/FREE Full Text
29. 29.↵
    2. Hulet SW,
    3. Heyliger SO,
    4. Powers S, et al

    . Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J Neurosci Res 2000;61:52–60 pmid:10861799

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Connor JR,
    3. Menzies SL

    . Relationship of iron to oligodendrocytes and myelination. Glia 1996;17:83–93 pmid:8776576

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Hametner S,
    3. Wimmer I,
    4. Haider L, et al

    . Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–61 doi:10.1002/ana.23974 pmid:23868451

    CrossRefPubMed
32. 32.↵
    2. Chen W,
    3. Gauthier SA,
    4. Gupta A, et al

    . Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271:183–92 doi:10.1148/radiol.13130353 pmid:24475808

    CrossRefPubMed
33. 33.↵
    2. Prineas JW,
    3. Kwon EE,
    4. Cho ES, et al

    . Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646–57 doi:10.1002/ana.1255 pmid:11706971

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Mehta V,
    3. Pei W,
    4. Yang G, et al

    . Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013;8:e57573 doi:10.1371/journal.pone.0057573 pmid:23516409

    CrossRefPubMed
35. 35.↵
    2. Chang A,
    3. Nishiyama A,
    4. Peterson J, et al

    . NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 2000;20:6404–12 pmid:10964946

    Abstract/FREE Full Text